Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.

Study answer

What this study found

Resveratrol did not improve GLP-1 secretion, gastric emptying, or glycemic control after 5 weeks. In the resveratrol arm, fasting GLP-1 changed from 36.8 to 35.4 pmol/L, peak GLP-1 from 52.7 to 55.1 pmol/L, glucose AUC from 2513 to 2545 mmol/L·min, HbA1c from 6.26% to 6.24%, and gastric half-emptying time from 165 to 163 min. Body weight was unchanged (81.1 to 81.2 kg), and no adverse events were reported. The authors concluded that resveratrol is unlikely to improve glycemic control in this population.

Study & population

Double-blind randomized crossover trial in adults with diet-controlled type 2 diabetes at the Royal Adelaide Hospital in Adelaide, Australia.

Intervention

Oral resveratrol capsules, 500 mg per dose twice daily, were given for 5 weeks in a double-blind randomized crossover design with a 5-week washout between treatment periods.

Key limitation

The intervention was short, with only 5-week treatment periods, which limits assessment of longer-term metabolic effects.

View full study detailsView sourceOpen PDF

Original abstract